Connect Biopharma initiates Phase 2 Seabreeze STAT study of rademikibart for acute asthma exacerbations

Connect Biopharma Holdings Ltd

Phase 2 Seabreeze STAT Asthma study (NCT06940141) initiated after FDA agreement on final protocol.
Evaluates rademikibart as adjunct to standard of care in ~160 adults/adolescents with type 2 inflammation asthma.
Primary endpoint: treatment failure rate over 28 days; secondary include exacerbations and lung function.
Topline data expected in first half of 2026.
Imminently on track to initiate a similarly-designed Phase 2 study in COPD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.